BACKGROUND/ OBJECTIVES: Interplay between the Hedgehog (HH) and epidermal growth factor receptor (EGFR) pathways modulating the outcome of their signaling activity have been reported in various cancers including pancreatic ductal adenocarcinoma (PDAC). Therefore, simultaneous targeting of these pathways may be clinically beneficial. This Phase I study combined HH and EGFR inhibition in metastatic PDAC patients. METHODS: Combined effects of HH and EGFR inhibition using Vismodegib and Erlotinib with or without gemcitabine in metastatic solid tumors were assessed by CT. Another cohort of patients with metastatic PDAC was evaluated by FDG-PET and tumor biopsies-derived biomarkers. RESULTS: Treatment was well tolerated with the maximum tolerated dose cohort experiencing no grade 4 toxicities though 25% experienced grade 3 adverse effects. Recommended phase II dose of Vismodegib and Erlotinib were each 150 mg daily. No tumor responses were observed although 16 patients achieved stable disease for 2-7 cycles. Paired biopsy analysis before and after first cycle of therapy in PDAC patients showed reduced GLI1 mRNA, phospho-GLI1 and associated HH target genes in all cases. However, only half of the cases showed reduced levels of desmoplasia or changes in fibroblast markers. Most patients had decreased phospho-EGFR levels. CONCLUSIONS: Vismodegib and Erlotinib combination was well-tolerated although overall outcome in patients with metastatic PDAC was not significantly impacted by combination treatment. Biomarker analysis suggests direct targets inhibition without significantly affecting the stromal compartment. These findings conflict with pre-clinical mouse models, and thus warrant further investigation into how upstream inhibition of these pathways is circumvented in PDAC.
BACKGROUND/ OBJECTIVES: Interplay between the Hedgehog (HH) and epidermal growth factor receptor (EGFR) pathways modulating the outcome of their signaling activity have been reported in various cancers including pancreatic ductal adenocarcinoma (PDAC). Therefore, simultaneous targeting of these pathways may be clinically beneficial. This Phase I study combined HH and EGFR inhibition in metastatic PDACpatients. METHODS: Combined effects of HH and EGFR inhibition using Vismodegib and Erlotinib with or without gemcitabine in metastatic solid tumors were assessed by CT. Another cohort of patients with metastatic PDAC was evaluated by FDG-PET and tumor biopsies-derived biomarkers. RESULTS: Treatment was well tolerated with the maximum tolerated dose cohort experiencing no grade 4 toxicities though 25% experienced grade 3 adverse effects. Recommended phase II dose of Vismodegib and Erlotinib were each 150 mg daily. No tumor responses were observed although 16 patients achieved stable disease for 2-7 cycles. Paired biopsy analysis before and after first cycle of therapy in PDACpatients showed reduced GLI1 mRNA, phospho-GLI1 and associated HH target genes in all cases. However, only half of the cases showed reduced levels of desmoplasia or changes in fibroblast markers. Most patients had decreased phospho-EGFR levels. CONCLUSIONS:Vismodegib and Erlotinib combination was well-tolerated although overall outcome in patients with metastatic PDAC was not significantly impacted by combination treatment. Biomarker analysis suggests direct targets inhibition without significantly affecting the stromal compartment. These findings conflict with pre-clinical mouse models, and thus warrant further investigation into how upstream inhibition of these pathways is circumvented in PDAC.
Authors: Natalia A Riobó; Ke Lu; Xingbin Ai; Gwendolyn M Haines; Charles P Emerson Journal: Proc Natl Acad Sci U S A Date: 2006-03-10 Impact factor: 11.205
Authors: David Cunningham; Ian Chau; Deborah D Stocken; Juan W Valle; David Smith; William Steward; Peter G Harper; Janet Dunn; Catrin Tudur-Smith; Julia West; Stephen Falk; Adrian Crellin; Fawzi Adab; Joyce Thompson; Pauline Leonard; Joe Ostrowski; Martin Eatock; Werner Scheithauer; Richard Herrmann; John P Neoptolemos Journal: J Clin Oncol Date: 2009-10-26 Impact factor: 44.544
Authors: Stephen J Murphy; Steven N Hart; Geoffrey C Halling; Sarah H Johnson; James B Smadbeck; Travis Drucker; Joema Felipe Lima; Fariborz Rakhshan Rohakhtar; Faye R Harris; Farhad Kosari; Subbaya Subramanian; Gloria M Petersen; Timothy D Wiltshire; Benjamin R Kipp; Mark J Truty; Robert R McWilliams; Fergus J Couch; George Vasmatzis Journal: Cancer Res Date: 2015-12-16 Impact factor: 12.701
Authors: Hua Tian; Christopher A Callahan; Kelly J DuPree; Walter C Darbonne; Christina P Ahn; Suzie J Scales; Frederic J de Sauvage Journal: Proc Natl Acad Sci U S A Date: 2009-02-25 Impact factor: 11.205
Authors: Harald Schnidar; Markus Eberl; Stefan Klingler; Doris Mangelberger; Maria Kasper; Cornelia Hauser-Kronberger; Gerhard Regl; Renate Kroismayr; Richard Moriggl; Maria Sibilia; Fritz Aberger Journal: Cancer Res Date: 2009-02-03 Impact factor: 12.701
Authors: Markus Eberl; Stefan Klingler; Doris Mangelberger; Andrea Loipetzberger; Helene Damhofer; Kerstin Zoidl; Harald Schnidar; Hendrik Hache; Hans-Christian Bauer; Flavio Solca; Cornelia Hauser-Kronberger; Alexandre N Ermilov; Monique E Verhaegen; Christopher K Bichakjian; Andrzej A Dlugosz; Wilfried Nietfeld; Maria Sibilia; Hans Lehrach; Christoph Wierling; Fritz Aberger Journal: EMBO Mol Med Date: 2012-02-01 Impact factor: 12.137
Authors: Maria Natalia Calienni; Daniela Maza Vega; C Facundo Temprana; María Cecilia Izquierdo; David E Ybarra; Ezequiel Bernabeu; Marcela Moretton; Fernando C Alvira; Diego Chiappetta; Silvia Del Valle Alonso; María Jimena Prieto; Jorge Montanari Journal: Pharmaceutics Date: 2021-02-01 Impact factor: 6.321